Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 95


Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3).

Ali AS, Grönberg M, Langer SW, Ladekarl M, Hjortland GO, Vestermark LW, Österlund P, Welin S, Grønbæk H, Knigge U, Sorbye H, Janson ET.

Med Oncol. 2018 Mar 6;35(4):47. doi: 10.1007/s12032-018-1103-x.


Health Economic Evaluation of Bevacizumab for Metastatic Colorectal Cancer [Internet].

Aaserud M, Kristiansen IS, Neilson AR, Norum J, Sørbye H, Aas E, Klemp Gjertsen M.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2007 Dec.


Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases.

Dasari A, Mehta K, Byers LA, Sorbye H, Yao JC.

Cancer. 2018 Feb 15;124(4):807-815. doi: 10.1002/cncr.31124. Epub 2017 Dec 6.


Treatment-related survival associations of claudin-2 expression in fibroblasts of colorectal cancer.

Mezheyeuski A, Strell C, Hrynchyk I, Guren TK, Dragomir A, Doroshenko T, Pashkova O, Gorgun J, Ruksha K, Pfeiffer P, Kure EH, Sorbye H, Edler D, Martling A, Glimelius B, Östman A, Portyanko A.

Virchows Arch. 2017 Nov 13. doi: 10.1007/s00428-017-2263-3. [Epub ahead of print]


Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma.

Ali AS, Grönberg M, Federspiel B, Scoazec JY, Hjortland GO, Grønbæk H, Ladekarl M, Langer SW, Welin S, Vestermark LW, Arola J, Österlund P, Knigge U, Sorbye H, Grimelius L, Janson ET.

PLoS One. 2017 Nov 7;12(11):e0187667. doi: 10.1371/journal.pone.0187667. eCollection 2017.


Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trial.

Labori KJ, Lassen K, Hoem D, Grønbech JE, Søreide JA, Mortensen K, Smaaland R, Sorbye H, Verbeke C, Dueland S.

BMC Surg. 2017 Aug 25;17(1):94. doi: 10.1186/s12893-017-0291-1.


Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9.

Winther SB, Österlund P, Berglund Å, Glimelius B, Qvortrup C, Sorbye H, Pfeiffer P; - on behalf of the Academy of Geriatric Cancer Research (AgeCare).

BMC Cancer. 2017 Aug 16;17(1):548. doi: 10.1186/s12885-017-3526-8.


High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer.

Siesing C, Sorbye H, Dragomir A, Pfeiffer P, Qvortrup C, Pontén F, Jirström K, Glimelius B, Eberhard J.

PLoS One. 2017 Aug 11;12(8):e0182512. doi: 10.1371/journal.pone.0182512. eCollection 2017.


A MUTYH germline mutation is associated with small intestinal neuroendocrine tumors.

Dumanski JP, Rasi C, Björklund P, Davies H, Ali AS, Grönberg M, Welin S, Sorbye H, Grønbæk H, Cunningham JL, Forsberg LA, Lind L, Ingelsson E, Stålberg P, Hellman P, Tiensuu Janson E.

Endocr Relat Cancer. 2017 Aug;24(8):427-443. doi: 10.1530/ERC-17-0196. Epub 2017 Jun 20.


Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status.

Thomsen M, Guren MG, Skovlund E, Glimelius B, Hjermstad MJ, Johansen JS, Kure E, Sorbye H, Pfeiffer P, Christoffersen T, Guren TK, Tveit KM.

Eur J Cancer. 2017 Aug;81:26-35. doi: 10.1016/j.ejca.2017.04.026. Epub 2017 Jun 6.


Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas.

Galleberg RB, Knigge U, Tiensuu Janson E, Vestermark LW, Haugvik SP, Ladekarl M, Langer SW, Grønbæk H, Österlund P, Hjortland GO, Assmus J, Tang L, Perren A, Sorbye H.

Eur J Surg Oncol. 2017 Sep;43(9):1682-1689. doi: 10.1016/j.ejso.2017.04.010. Epub 2017 May 4.


Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study.

Guren TK, Thomsen M, Kure EH, Sorbye H, Glimelius B, Pfeiffer P, Österlund P, Sigurdsson F, Lothe IMB, Dalsgaard AM, Skovlund E, Christoffersen T, Tveit KM.

Br J Cancer. 2017 May 9;116(10):1271-1278. doi: 10.1038/bjc.2017.93. Epub 2017 Apr 11.


ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms. Systemic Therapy 2: Chemotherapy.

Garcia-Carbonero R, Rinke A, Valle JW, Fazio N, Caplin M, Gorbounova V, O Connor J, Eriksson B, Sorbye H, Kulke M, Chen J, Falkerby J, Costa F, de Herder W, Lombard-Bohas C, Pavel M; Antibes Consensus Conference participants.

Neuroendocrinology. 2017;105(3):281-294. doi: 10.1159/000473892. Epub 2017 Apr 5. No abstract available.


ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents.

Pavel M, Valle JW, Eriksson B, Rinke A, Caplin M, Chen J, Costa F, Falkerby J, Fazio N, Gorbounova V, de Herder W, Kulke M, Lombard-Bohas C, O'Connor J, Sorbye H, Garcia-Carbonero R; Antibes Consensus Conference Participants; Antibes Consensus Conference participants.

Neuroendocrinology. 2017;105(3):266-280. doi: 10.1159/000471880. Epub 2017 Mar 29. No abstract available.


ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology: Diagnosis and Prognostic Stratification.

Perren A, Couvelard A, Scoazec JY, Costa F, Borbath I, Delle Fave G, Gorbounova V, Gross D, Grossma A, Jense RT, Kulke M, Oeberg K, Rindi G, Sorbye H, Welin S; Antibes Consensus Conference participants.

Neuroendocrinology. 2017;105(3):196-200. doi: 10.1159/000457956. Epub 2017 Feb 11. No abstract available.


Population-based study on resection rates and survival in patients with colorectal liver metastasis in Norway.

Angelsen JH, Horn A, Sorbye H, Eide GE, Løes IM, Viste A.

Br J Surg. 2017 Apr;104(5):580-589. doi: 10.1002/bjs.10457. Epub 2017 Feb 9.


A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer.

Dimcevski G, Kotopoulis S, Bjånes T, Hoem D, Schjøtt J, Gjertsen BT, Biermann M, Molven A, Sorbye H, McCormack E, Postema M, Gilja OH.

J Control Release. 2016 Dec 10;243:172-181. doi: 10.1016/j.jconrel.2016.10.007. Epub 2016 Oct 12.


Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer.

Thomsen M, Kersten C, Sorbye H, Skovlund E, Glimelius B, Pfeiffer P, Johansen JS, Kure EH, Ikdahl T, Tveit KM, Christoffersen T, Guren TK.

Oncotarget. 2016 Nov 15;7(46):75013-75022. doi: 10.18632/oncotarget.12601.


Corrigendum to "2nd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer" [Eur J Cancer 63 (August 2016) 11-24].

Lutz MP, Zalcberg JR, Glynne-Jones R, Ruers T, Ducreux M, Arnold D, Aust D, Brown G, Bujko K, Cunningham C, Evrard S, Folprecht G, Gerard JP, Habr-Gama A, Haustermans K, Holm T, Kuhlmann KF, Lordick F, Mentha G, Moehler M, Nagtegaal ID, Pigazzi A, Pucciarelli S, Roth A, Rutten H, Schmoll HJ, Sorbye H, Van Cutsem E, Weitz J, Otto F.

Eur J Cancer. 2016 Nov;68:208-209. doi: 10.1016/j.ejca.2016.08.017. Epub 2016 Oct 4. No abstract available.


TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer.

Tarpgaard LS, Ørum-Madsen MS, Christensen IJ, Nordgaard C, Noer J, Guren TK, Glimelius B, Sorbye H, Ikdahl T, Kure EH, Tveit KM, Nielsen HJ, Pfeiffer P, Brünner N, Moreira JM.

Oncotarget. 2016 Sep 13;7(37):59441-59457. doi: 10.18632/oncotarget.11118.

Supplemental Content

Loading ...
Support Center